Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report

被引：30
作者：
Barth, Matthew J. [1 ]
Goldman, Stanton [2 ]
Smith, Lynette [3 ]
Perkins, Sherrie [4 ]
Shiramizu, Bruce [5 ]
Gross, Thomas G. [6 ]
Harrison, Lauren [7 ]
Sanger, Warren [8 ]
Geyer, Mark B. [9 ]
Giulino-Roth, Lisa [10 ,11 ]
Cairo, Mitchell S. [7 ,12 ,13 ,14 ,15 ]
机构：
[1] SUNY Coll Buffalo, Div Pediat Hematol Oncol, Buffalo, NY 14222 USA
[2] Med City Childrens Hosp, Div Pediat Hematol Oncol, Dallas, TX USA
[3] Univ Nebraska, Coll Publ Hlth, Dept Biostat, Omaha, NE 68182 USA
[4] Univ Utah, Dept Pathol, Salt Lake City, UT USA
[5] Univ Hawaii, Div Pediat Hematol Oncol, Honolulu, HI 96822 USA
[6] Ohio State Univ, Div Pediat Hematol Oncol Blood & Marrow Transplan, Columbus, OH 43210 USA
[7] New York Med Coll, Dept Pediat, Valhalla, NY 10595 USA
[8] Univ Nebraska Med Ctr, Dept Cytogenet, Omaha, NE USA
[9] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp, Boston, MA USA
[10] Weill Cornell Med Coll, Dept Pediat, Div Pediat Hematol Oncol, New York, NY USA
[11] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA
[12] New York Med Coll, Dept Med, Valhalla, NY 10595 USA
[13] New York Med Coll, Dept Pathol, Valhalla, NY 10595 USA
[14] New York Med Coll, Dept Microbiol, Valhalla, NY 10595 USA
[15] New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2013年 / 162卷 / 05期
基金：
美国国家卫生研究院;
关键词：
non-Hodgkin lymphoma; rituximab; pharmacokinetics; pediatric; CD20; NON-HODGKINS-LYMPHOMA; SERUM CONCENTRATIONS; RISK; IDEC-C2B8;
D O I：
10.1111/bjh.12434
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The ANHL01P1 trial was undertaken to determine pharmacokinetics and safety following the addition of rituximab to French-American-British/Lymphome Malins de Burkitt (FAB/LMB96) chemotherapy in 41 children and adolescents with Stage III/IV mature B-cell lymphoma/leukaemia. Patients received rituximab (375mg/m(2)) days -2 and 0 of two induction cycles and day 0 of two consolidation cycles. Highest peak levels were achieved following the second dose of each induction cycle [299 +/- 19 and 384 +/- 25 mu g/ml (Group-B); 245 +/- 31 and 321 +/- 32g/ml (Group-C)] with sustained troughs and t1/2 of 26-29d. Rituximab can be safely added to FAB chemotherapy with high early rituximab peak/trough levels and a long t1/2.
引用
收藏
页码：678 / 683
页数：6
相关论文
共 14 条
  • [1] Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura
    Bennett, CM
    Rogers, ZR
    Kinnamon, DD
    Bussel, JB
    Mahoney, DH
    Abshire, TC
    Sawaf, H
    Moore, TB
    Loh, ML
    Glader, BE
    McCarthy, MC
    Mueller, BU
    Olson, TA
    Lorenzana, AN
    Mentzer, WC
    Buchanan, GR
    Feldman, HA
    Neufeld, EJ
    [J]. BLOOD, 2006, 107 (07) : 2639 - 2642
  • [2] Safety, kinetics, and outcome following rituximab (R) in combination with FAB chemotherapy in children and adolescents (C plus A) with stage III/IV (Group B) and BM plus /CNS plus (Group C) mature B-NHL: A Children's Oncology Group report.
    Cairo, M. S.
    Lynch, J. C.
    Harrison, L.
    Perkins, S. L.
    Shiramizu, B.
    Gross, T. G.
    Sanger, W.
    Goldman, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents
    Cairo, Mitchell S.
    Gerrard, Mary
    Sposto, Richard
    Auperin, Anne
    Pinkerton, C. Ross
    Michon, Jean
    Weston, Claire
    Perkins, Sherrie L.
    Raphael, Martine
    McCarthy, Keith
    Patte, Catherine
    [J]. BLOOD, 2007, 109 (07) : 2736 - 2743
  • [4] Advanced Stage, Increased Lactate Dehydrogenase, and Primary Site, but Not Adolescent Age (≥ 15 Years), Are Associated With an Increased Risk of Treatment Failure in Children and Adolescents With Mature B-Cell Non-Hodgkin's Lymphoma: Results of the FAB LMB 96 Study
    Cairo, Mitchell S.
    Sposto, Richard
    Gerrard, Mary
    Auperin, Anne
    Goldman, Stanton C.
    Harrison, Lauren
    Pinkerton, Ross
    Raphael, Martine
    McCarthy, Keith
    Perkins, Sherrie L.
    Patte, Catherine
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04) : 387 - 393
  • [5] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier, B
    Lepage, E
    Brière, J
    Herbrecht, R
    Tilly, H
    Bouabdallah, R
    Morel, P
    Van den Neste, E
    Salles, G
    Gaulard, P
    Reyes, F
    Gisselbrecht, C
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) : 235 - 242
  • [6] Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20
    Dayde, David
    Ternant, David
    Ohresser, Marc
    Lerondel, Stephanie
    Pesnel, Sabrina
    Watier, Herve
    Le Pape, Alain
    Bardos, Pierre
    Paintaud, Gilles
    Cartron, Guillaume
    [J]. BLOOD, 2009, 113 (16) : 3765 - 3772
  • [7] Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report
    Goldman, S.
    Smith, L.
    Anderson, J. R.
    Perkins, S.
    Harrison, L.
    Geyer, M. B.
    Gross, T. G.
    Weinstein, H.
    Bergeron, S.
    Shiramizu, B.
    Sanger, W.
    Barth, M.
    Zhi, J.
    Cairo, M. S.
    [J]. LEUKEMIA, 2013, 27 (05) : 1174 - 1177
  • [8] Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response
    Jaeger, Ulrich
    Fridrik, Michael
    Zeitlinger, Markus
    Heintel, Daniel
    Hopfinger, Georg
    Burgstaller, Sonja
    Mannhalter, Christine
    Oberaigner, Wilhelm
    Porpaczy, Edit
    Skrabs, Cathrin
    Einberger, Christine
    Drach, Johannes
    Raderer, Markus
    Gaiger, Alexander
    Putman, Monique
    Greil, Richard
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (09): : 1431 - 1438
  • [9] Maloney DG, 1997, BLOOD, V90, P2188
  • [10] Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin's Lymphoma and Burkitt Leukemia
    Meinhardt, Andrea
    Burkhardt, Birgit
    Zimmermann, Martin
    Borkhardt, Arndt
    Kontny, Udo
    Klingebiel, Thomas
    Berthold, Frank
    Janka-Schaub, Gritta
    Klein, Christoph
    Kabickova, Edita
    Klapper, Wolfram
    Attarbaschi, Andishe
    Schrappe, Martin
    Reiter, Alfred
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) : 3115 - 3121
12